Minocycline and Tobacco Craving in Smokers With Schizophrenia
Status:
Completed
Trial end date:
2019-07-23
Target enrollment:
Participant gender:
Summary
Craving for cigarettes is an important aspect that leads to challenges with smoking
cessation. Persons with schizophrenia are more likely to smoke and to be heavier smokers than
persons without schizophrenia, and may experience craving differently as well. Minocycline is
an antibiotic medication that may impact craving. We will conduct a two-week randomized,
double-blind, placebo-controlled, parallel group pilot study to investigate the effects of
minocycline vs. placebo on craving and smoking behaviors in smokers with schizophrenia.
Participants will take minocycline or matching placebo for two weeks. Participants will be
assessed on aspects of craving and smoking behavior at baseline and after 1 and 2 weeks of
minocycline or placebo treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore